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Strengths and limitations of this study
 ► The main strength of this study was the use of na-
tional register data comprising all combined oral 
contraceptive prescriptions in Norway.
 ► Large dataset with reliable information about pre-
scriptions (endpoint) and prescribers (exposure).
 ► Minimal, if any, recall bias or misclassification bias 
as the endpoint and exposure are registered as pre-
scribed by prescribers rather than as reported by 
users.
 ► A 4- year, register- based ‘wash- out’ window before 
study start minimalised misclassification bias of 
‘starters’.
 ► Online prescriptions from abroad are not included 
in the register data. We consider this limitation to 
be minimal, as hormonal contraceptives are easily 
available and affordable.
AbStrACt
Objectives To assess whether changes in patterns of 
combined oral contraceptive (COC) prescriptions to starters 
between 2008 and 2016 were in line with changes in 
national recommendations for use.
Design Historical prospective cohort study.
Setting The national Norwegian Prescription Database.
Participants Women aged 10–49 years who started 
COCs between 1 January 2008 and 30 June 2016, in total 
285 009 women.
Primary outcome The proportion of levonorgestrel- 
containing COC prescriptions to starters.
Intervention The Norwegian Medical Agency 
recommended levonorgestrel- containing COCs to starters 
from 2010 onwards.
results The proportion of levonorgestrel- containing COCs 
prescribed to starters increased from 41% in 2008 to 80% 
in 2016 with the greatest increase from 2011 to 2012. 
This prescription pattern comprised all age groups but was 
observed to a lower extent among older women. Public 
health nurses and midwifes had the highest compliance 
with recommendations and prescribed levonorgestrel- 
containing COCs to 96% of starters aged <20 years in 
2016, compared with 75% and 86% among general 
practitioners and doctors with no specialty.
Conclusion All professions have increased the proportion 
of levonorgestrel- containing COC prescriptions to starters. 
Public health nurses and midwives had the highest 
compliance with the new recommendations. Future 
studies will examine whether this shift in prescription 
pattern has prevented venous thromboembolism in women 
of reproductive age in Norway.
IntrODuCtIOn
Venous thromboembolism (VTE) is a serious, 
though rare, complication of combined oral 
contraceptives (COCs).1 The first COCs were 
launched in the early 1960s.2 Since then, 
the oestrogen dose they contain has signifi-
cantly decreased, as prothrobotic proper-
ties were thought to be associated more 
with the oestrogen component than the 
gestagen (synthetic progestins) component. 
This replacement proved highly effective 
in reducing the risk of thrombosis,3 while a 
further decrease from 30 to 20 µg ethinyl 
estradiol has had a limited impact on VTE 
risk.4–6
From 1995, the gestagen component of 
COCs has received more attention, as three 
independent studies of that time reported 
significantly different VTE risks by type of 
gestagen.7–9 Numerous studies on COCs 
containing gestoden and desogestrel, and 
later drospirenone, have reported a VTE 
risk that was twice that observed in COCs 
containing levonorgestrel.4–6 10–14 The VTE 
risk associated with COCs containing the 
newest gestagens, dienogest and nomege-
strol, is not yet known.15
The prothrombotic effect of COCs is mainly 
related to the dose of oestrogen they contain, 
but gestagen seems to reverse this effect.16 
It has been theorised that various gesta-
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Table 1  Characteristics of starters and prescribers of combined oral contraceptives, 2008–2016 (%)
2008 2009–2010 2011–2012 2013–2014 2015–2016*
n=38 128 n=70 244 n=65 796 n=64 649 n=46 192
% % % % %
Starter age (years)
  <20 58.4 62.5 63.2 64.2 65.4
  20–24 12.8 12.3 14.0 14.7 14.9
  25–29 11.0 9.1 8.3 7.8 7.5
  30–34 9.0 7.6 6.6 5.9 5.6
  35–49 8.7 8.5 8.0 7.4 6.7
Health region (residence)
  Southern/eastern Norway 53.4 53.2 53.5 53.4 53.1
  Western Norway 22.5 23.0 22.8 22.8 23.3
  Central Norway 14.4 14.3 14.2 14.4 14.4
  Northern Norway 9.6 9.5 9.5 9.5 9.3
Prescriber
  Doctors with no specialty 21.9 23.7 27.7 31.9 33.5
  General practitioners 42.1 37.3 35.1 32.7 31.1
  Gynaecologists 8.9 7.9 7.5 7.0 6.9
  Doctors with other specialties 6.7 4.8 3.9 3.6 3.6
  Public health nurses/midwives 20.4 26.3 25.8 24.9 24.9
*Until 30 June 2016.
prothrombotic effect of oestrogen and that levonorgestrel 
is more effective at reversing this effect than the newer 
gestagens.16 One theory for this mechanism is the effect 
of gestagens on the quantity of sex hormone- binding 
globulin, which reflects the level of ‘oestrogenisity’ in the 
blood, as levonorgestrel reduces this quantity to a greater 
extent than newer gestagens.17–19
Given the lack of solid pharmacovigilance data, medical 
agencies around the world have hesitated to change their 
recommendations of COC use. In 2009, the Norwegian 
Medicines Agency (NOMA) found that the evidence was 
strong enough to recommend COCs with levonorgestrel to 
starters.20 In 2010, NOMA initiated a campaign in collab-
oration with the Norwegian Directorate of Health and 
the companies that sold COCs in Norway. It comprised 
letters to various prescribers (physicians, public health 
nurses and midwifes). Facebook and Twitter groups were 
established with known bloggers, and new packaging for 
COCs included a warning on VTE symptoms and risks. 
The aim of this study was to assess whether changes in 
patterns of COC prescriptions to starters between 2008 
and 2016 were in line with changes in national recom-
mendations for use.
MAterIAl AnD MethODS
We used a historical prospective cohort design to analyse 
data from the Norwegian Prescription Database (NorPD). 
NorPD was established on 1 January 2004. All pharmacies 
take part in the compulsory, electronic reporting to this 
registry, which contains information on prescriptions, 
prescribed drugs delivered by pharmacies to users, users 
and prescribers.21 NorPD includes detailed information 
about the prescribed drug, date of delivery and location 
of the pharmacy; user information on month and year 
of birth, gender and home municipality; and prescriber 
information on year of birth, gender, profession and 
subspecialisation. When prescriptions are recorded in 
NorPD, the personal identification number of the user 
and the prescriber is replaced with a pseudonym.
A total of 939 469 women had at least one prescrip-
tion for hormonal contraceptives registered in NorPD 
between 1 January 2004 and 30 June 2016. We excluded 
women who did not have any prescriptions for COCs 
in this period (n=282 104) and women who used COCs 
before 2008 (n=370 517). Finally, we excluded women 
with prescriptions from pharmacists/veterinarians 
(n=65), women aged ≥50 years (n=519), women with 
prescriptions with missing user age (n=313) and women 
with prescriptions missing prescriber ID (n=942). After 
these exclusions, 285 009 women were eligible for inclu-
sion in the analysis.
COCs are categorised as pills that contain one of the 
following gestagens: levonorgestrel, norethisterone, 
desogestrel, drospirenone or dienogest/nomegestrol. 
Period and age at first COC prescription were catego-
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Table 2  Proportion of different types of combined oral contraceptives prescribed to starters, 2008–2016 (%)
2008 2009–2010 2011–2012 2013–2014 2015–2016*
n=38 128 n=70 244 n=65 796 n=64 649 n=46 192
% % % % %
Type of gestagen
  Levonorgestrel 41.4 37.3 55.2 73.3 79.3
  Noretisterone 6.5 3.4 2.2 1.7 1.4
  Desogestrel 28.6 37.1 25.9 11.9 7.5
  Drospirenone 23.5 21.6 15.5 12.0 11.1
  Dienogest 0.7 0.9 0.6 0.5
  Nomegestrol 0.3 0.4 0.3
Gestagen/oestrogen content
  Levonorgestrel/20 μg EE 25.1 22.3 31.0 42.0 46.4
  Levonorgestrel/30 μg EE 16.3 15.0 24.2 31.3 32.8
  Noretisterone/35 μg EE 6.5 3.4 2.2 1.7 1.4
  Desogestrel/20 μg EE 27.0 35.5 24.7 11.0 6.8
  Desogestrel/30 μg EE 1.7 1.6 1.1 0.9 0.7
  Drospirenone/20 μg EE 6.9 8.5 6.8 5.7 5.2
  Drospirenone/30 μg EE 16.6 13.1 8.6 6.3 5.8
  Dienogest/3+2+2+1 mg oestradiol valerate 0.7 0.9 0.6 0.5
  Nomegestrol/1.5 mg oestradiol 0.3 0.4 0.3
*Until 30 June 2016 .
EE, ethinyloestradiol.
2013–2014 and 2015-2016/10–14, 15–19, 20–24, 25–29, 
30–34 and 35–49 years). Residence was used to determine 
the health region (Southern/Eastern, Western, Central 
and Northern) of users. Information on prescribers’ age 
(≤29, 30–39, 40–49, 50–59 and ≥60 years), gender (male 
or female) and profession was also included. Profession 
was categorised as doctor with no specialty, general prac-
titioner, gynaecologist, doctor with other specialty and 
public health nurse/midwife. Doctors with no specialty 
included doctors in specialisation, postgraduate students 
from medical school doing their internship and medical 
students who had a valid licence issued from the fifth year 
of medical school. Doctors with more than one specialty 
were assigned to the most recent specialty. Public health 
nurses and midwives had the right to prescribe COCs to 
women aged 16–19 years only.
All analyses were done in Statistical Package for Social 
Sciences V.22.0 with χ2 test for trend for categorical vari-
ables at a significance level p<0.05. We defined starters 
as women who used COCs for the first time ever. When 
estimating the annual proportion of starters, we applied 
data from NorPD for starters as the numerator and data 
for the entire female population aged 15–49 years from 
Statistics Norway as the denominator. In these estimates, 
adjustments were made for starters in previous years.
Patient and public involvement
As the study was register- based, the research question 
and outcome measures were not informed by any specific 
patient priorities, experiences or preferences. This study 
used only data from NorPD and thus did not include a 
recruitment process for patients; therefore, patients were 
not involved in the design or the conduct of the study.
reSultS
Over the study period (complete years 2008–2015) the 
prevalence of COC use (20.1%–20.3%) and the propor-
tion of starters of COCs (3.2%–3.3%) among women of 
reproductive age (15–49 years) were remarkably stable. 
The proportion of starters among all women filling a 
COC prescription decreased significantly from 17.0% 
to 12.7% between 2008 and 2015. This proportion was 
fairly constant among women aged 15–19 years (34.1%–
35.0%), while a decrease was observed in the proportion 
of starters among all women filling a prescription of COCs 
in older age groups across the study period (decreasing 
from 7.0%–13.0% to 4.5%–7.1%) .
Most starters were aged below 20 years, and there was a 
relative increase in the proportion of starters among the 
youngest women (table 1, upper panel). The proportion 
of prescriptions of COC to starters in the different health 
regions was very stable over the study period (table 1, 
central panel). While general practitioners were the main 
prescribers of COCs at the beginning of the study period, 
doctors with no specialty had the highest proportion of 
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Figure 1 Proportion of COC prescriptions to starters 
by type of gestagen, 2008–2016. COC, combined oral 
contraceptive.
Figure 2 Proportion of COC prescriptions containing 
levonorgestrel to starters by age, 2008–2016. COC, 
combined oral contraceptive.
study period (table 1, lower panel). Public health nurses 
and midwives prescribed approximately 25% of COCs to 
starters. COC prescriptions to starters by gynaecologists 
were low and decreased slightly over time. Doctors with 
other specialties had the lowest proportion of prescrip-
tions of COC to starters (table 1, lower panel).
The age of prescribers gradually increased during the 
study period for all professions, except for doctors with 
no specialty. Among the main prescribers of COCs to 
starters, there were minimal differences in gender, except 
for public health nurses and midwives, who were almost 
100% women.
Levonorgestrel was the most common gestagen in 
the COCs prescribed throughout the study period. 
The proportion of prescriptions with levonorgestrel- 
containing COCs to starters increased from 41% in 2008 
to 80% in 2016 (table 2, upper panel, and figure 1) (χ2- 
trend, p<0.001), with the greatest increase occurring 
from 2011 to 2012. In 2012, the proportion of prescrip-
tions with levonorgestrel- containing COCs to starters 
became greater than the proportions of prescriptions 
with desogestrel- containing and drospirenone- containing 
COCs combined. After 2012, the proportion of prescrip-
tions with levonorgestrel- containing COCs increased 
gradually, but the increase was smaller in the last years 
of the study period (figure 1). Prescriptions of dienogest- 
containing and nomegestrol- containing COCs to starters 
represented less than 1% of investigated prescriptions 
during the study period, and the proportion of prescrip-
tions of norethisterone- containing COCs decreased 
(table 2, upper panel, and figure 1).
The proportion of starters who were prescribed COCs 
with the lowest dose of oestrogen did not change during 
the study period (table 2, lower panel). The prescrip-
tion rate of levonorgestrel- containing COCs increased in 
similar terms for pills with both 20 and 30 µg oestrogen, 
while the prescription rate of COCs containing other 
gestagens, independent of oestrogen dose, decreased.
The proportion of prescriptions of levonorgestrel- 
containing COCs increased among starters in all age 
groups (figure 2) (χ2- trend, p<0.001; age- stratified anal-
yses). The differences between the various age groups 
were small before 2012, but after that, a larger increase 
was observed among the youngest starters (<20 and 20–24 
years). The proportion of prescriptions of levonorgestrel- 
containing COCs decreased with increasing age of starters. 
In 2016, the proportion of prescriptions of levonorgestrel- 
containing COCs ranged from 65% among starters aged 
≥35 years to 85% among starters aged <20 years (figure 2).
There were small differences in the prescription rate 
of levonorgestrel- containing COCs across the various 
professions before 2012, but thereafter, greater differ-
ences in compliance with the national recommendations 
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Figure 4 Proportion of COC prescriptions containing 
levonorgestrel to starters ≥20 years by profession, 2008–
2016. COC, combined oral contraceptive.
Figure 3 Proportion of COC prescriptions containing 
levonorgestrel to starters <20 years by profession, 2008–
2016. COC, combined oral contraceptive.
were only able to prescribe to women aged between 16 
and 19 years, had had the highest prescription rate of 
levonorgestrel- containing COCs to starters: 96% in 2016 
(figure 3). In contrast, the other main prescribers, general 
practitioners and doctors with no specialty, increased 
their prescription rate of levonorgestrel- containing COCs 
to 75% and 86% among starters aged <20 years. Gynaecol-
ogists followed the same prescription pattern to starters as 
general practitioners. Doctors with other specialties had 
the lowest prescription rate of levonorgestrel- containing 
COCs to starters aged <20 years throughout the study 
period, and the rate increased to 59% in 2016 (figure 3).
All professions showed decreasing prescription rates 
of levonorgestrel- containing COCs with increasing 
age of starters. The increase in the prescription rate of 
levonorgestrel- containing COCs was less marked among 
starters aged >20 years (figure 4) than among starters aged 
<20 years (figure 3) for all professions. The greatest differ-
ence in the prescription rate of levonorgestrel- containing 
COCs between starters aged <20 and >20 years was seen 
among gynaecologists, who had the lowest prescription 
rate of levonorgestrel- containing COCs, together with 
doctors with other specialties, throughout the study 
period (figures 3 and 4). The majority of prescriptions 
from gynaecologists were to starters aged 25–49 years, 
while general practitioners and doctors with no and other 
specialties had a more even distribution of prescriptions 
to starters in the age groups 20–24 and 25–49 years.
DISCuSSIOn
The proportion of prescription of levonorgestrel- 
containing COCs to starters has, independent of 
oestrogen dose, increased from 41% in 2008 to 80% in 
2016, with the greatest increase observed from 2011 to 
2012. This may be related to the updated recommen-
dations published by NOMA in 2010, which stated that 
levonorgestrel- containing COCs should be the first 
choice for starters because of the lower VTE risk. The fact 
that four out of five starters obtained the recommended 
COCs in the first half of 2016 shows high compliance with 
these recommendations.
The greatest increase in the prescription rate of recom-
mended COCs was seen among the youngest starters (<20 
years and 20–24 years); the proportion of prescriptions 
of levonorgestrel- containing COCs decreased with the 
increasing age of starters. Some women included in the 
study, mainly in the oldest age groups, may have used 
COCs before 2004 and may be ‘restarters’. The restarters 
in this study would have had a break of at least 4 years, 
and thus levonorgestrel- containing COCs should be the 
first choice based on the VTE risk. Nevertheless, restarters 
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want, and this may explain the differences in prescription 
patterns among women across age groups.
Public health nurses and midwives, who only had 
the right to prescribe COCs to women between 16 and 
19 years of age, had the highest prescription rate of 
levonorgestrel- containing COCs to starters: 96% in 2016. 
This suggests that midwives and public health nurses 
may be more aware of and have better compliance in 
general with best practice recommendations than other 
prescribers. The other main prescribers, doctors with no 
specialty and general practitioners, prescribed the recom-
mended COCs to 86% and 75% of starters aged <20 years 
in 2016. General practitioners especially may increase 
their prescription rate of levonorgestrel- containing 
COCs to further increase the total proportion of starters 
obtaining COCs with the lowest risk of VTE. Although 
gynaecologists and doctors with other specialties had 
the lowest proportion of prescriptions of levonorgestrel- 
containing COCs to starters, they contributed a small 
number of prescriptions overall, and their prescription 
volume was less important for overall use.
All professions prescribed recommended COCs less 
often to older starters. The greatest difference in prescrip-
tions between starters below and above 20 years of age was 
seen among gynaecologists, but they probably provide 
more prescriptions to restarters compared with the other 
professions, since gynaecologists have a higher volume of 
prescriptions to older women.
The strength of this study is the large dataset, with reli-
able information about prescriptions and prescribers, 
and that all pharmacies take part in the compulsory, 
electronic reporting of prescriptions to NorPD. More-
over, only a few women were excluded from the analysis. 
Other strengths include the elimination of recall bias on 
the type of COC used, as this was a register- based study, 
and the near elimination of misclassification of starters by 
having a 4- year window of exposure before study start. A 
possible limitation of the study is that filled prescriptions 
do not necessarily mean that the medication was actually 
taken. As 91.5% of the study participants had one refill 
and 83.9% had two refills of a hormonal method within 
timely intervals of first initiation of COCs, we find it 
reasonable to state that the sales database NorPD reflects 
real use. Indeed, Triebwasser et al reported that pharmacy 
claims are more reliable than self- reported contraceptive 
use, which is often overestimated.22
The medical product agencies in Sweden and Denmark 
also updated their recommendations based on the increasing 
scientific evidence regarding a differential risk of VTE with 
COC with different gestagens, but Finland and Iceland still 
have no national guidelines.23 Compared with Norway, 
where levonorgestrel- containing COCs constituted a larger 
proportion than before, the share of the recommended 
products increased to a larger extent in Denmark, from 
13% of overall sales of COCs in 2010 to 50% in 2013. Danish 
studies that showed an association between gestagens and 
VTE4 5 received more attention in Denmark than in the other 
Nordic countries, and this may explain the larger increase in 
this country. In Iceland, the total proportion of prescriptions 
of levonorgestrel- containing COCs increased; in Finland, 
it remained below 1%, contrasting with a slight decrease 
in Sweden.23 Compared with the other Nordic countries, 
the changes in the prescription pattern of COCs in Norway 
and Denmark following updated recommendations may be 
considered a success. Moreover, the increased proportion of 
prescriptions of levonorgestrel- containing COCs in Norway 
has probably led to a decreased incidence of VTE among 
young women, and this will be addressed in future studies.
COnCluSIOn
The total proportion of starters who obtained levonorgestrel- 
containing COCs increased from 41% in 2008 to 80% in 
2016, with the greatest increase from 2011 to 2012. All 
professions increased their proportion of prescriptions 
of recommended COCs, mainly among the youngest 
starters, with the highest compliance with recommenda-
tions observed among public health nurses and midwives. 
Norwegian health personnel do comply relatively well with 
the new recommendations, but general practitioners may 
prescribe a larger proportion of levonorgestrel- containing 
COCs to starters to further increase the population of users 
with the lowest risk of VTE.
ArtICle SuMMAry
A large- scale national pharmacovigilance campaign had 
a major impact on the pattern of COC prescriptions in 
Norway.
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